3 results match your criteria: "Saint John Regional Hospital (MM)[Affiliation]"
Hypofractionated Dose Escalation Radiotherapy for High-risk Prostate Cancer: The Survival Analysis of the Prostate Cancer Study 5, a Groupe de Radio-oncologie Génito-urinaire du Quebec-led Phase 3 Trial.
Eur Urol
September 2024
Saint John Regional Hospital (MM), Saint John, New Brunswick, Canada.
Article Synopsis
- The Prostate Cancer Study 5 (PCS5) aimed to compare the effectiveness and side effects of two types of radiotherapy: conventional fractionated radiotherapy (CFRT) and hypofractionated radiotherapy (HFRT) for high-risk prostate cancer patients.
- The study included 329 patients who were randomly assigned to receive either CFRT or HFRT, with the primary focus on comparing toxicity and secondary outcomes like survival rates over a 5-year median follow-up.
- Results showed no significant differences in overall survival or other survival metrics between the two treatments, suggesting that HFRT could be adopted as a new standard treatment option for high-risk patients.
Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Génito-Urinaire de Quebec Led Phase 3 Trial.
Int J Radiat Oncol Biol Phys
January 2024
Department of Oncology, Division of Radiation Onclogy, Saint John Regional Hospital (MM), Saint John, New Brunswick, Canada.
Article Synopsis
- The study evaluates the safety of moderate hypofractionated radiation therapy (HF RT) compared to standard fractionation (SF RT) in high-risk prostate cancer patients, based on the hypothesis that HF RT may offer advantages due to prostate cancer's sensitivity to radiation.
- From February 2012 to March 2015, 329 high-risk patients participated in a trial, with participants randomized into HF and SF groups, both receiving androgen deprivation therapy, and researchers primarily focused on monitoring acute and delayed toxicity.
- Results indicated that while there were initially more acute gastrointestinal (GI) events in the HF group, this significance diminished over time; ultimately, no major differences in delayed GI-related adverse events were observed
The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients.
J Urol
June 2021
Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Article Synopsis
- Long-term androgen deprivation therapy in men with high-risk prostate cancer is linked to a decrease in bone mineral density, but this does not significantly increase the risk of fractures.
- A study analyzed the bone mineral density changes after 28 months of therapy and supplementation with calcium and vitamin D in patients, revealing an average decrease of -3.2% across multiple sites without significant classification changes for most patients.
- The findings suggest that while there is a slight reduction in bone mineral density, calcium and vitamin D supplementation is generally effective in managing bone health for these patients on long-term therapy.